10 completed, 3 active not recruiting, 3 recruiting, 2 not yet recruiting. 22 Phase 3, 6 Phase 2.
Follow Blindness: new trials by email Literature Review of Blindness trials Research Report on Blindness
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome N-acetylcysteine amide, Placebo - Retinitis Pigmentosa (RP), Usher Syndrome | Phase 3 | Not yet recruiting | Nacuity Pharmaceuticals, Inc. | 80 | 2026-12-01 | 2026-07-01 |
| A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome Placebo, NPI-001 - Retinitis Pigmentosa (RP), Usher Syndrome | Phase 3 | Recruiting | Nacuity Pharmaceuticals, Inc. | 80 | 2026-10-23 | 2026-11-10 |
| Clinical Investigation of Safety and Effectiveness for the enVVe® System envve system - Chronic Venous Insufficiency, CVI | Phase 2 / Phase 3 | Not yet recruiting | Hancock Jaffe Laboratiores, Inc | 220 | 2026-07-01 | 2026-05-27 |
| Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) Ixo-vec, Aflibercept - Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD | Phase 3 | Recruiting | Adverum Biotechnologies, Inc. | 534 | 2026-03-16 | 2026-09-24 |
| Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) sepofarsen, Placebo IVT - Leber Congenital Amaurosis 10, Blindness | Phase 3 | Recruiting | Laboratoires Thea | 32 | 2025-06-04 | 2026-10-21 |
| Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration Ixo-vec, Aflibercept - Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD | Phase 3 | Active not recruiting | Adverum Biotechnologies, Inc. | 311 | 2025-02-28 | 2026-05-22 |
| Oral N-acetylcysteine for Retinitis Pigmentosa N-acetylcysteine, Placebo - Retinitis Pigmentosa | Phase 3 | Active not recruiting | Johns Hopkins University | 485 | 2023-10-11 | 2026-06-15 |
| Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste) QR-421a, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 5 | 2021-12-15 | 2024-08-07 |
| Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius) Ultevursen, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 7 | 2021-12-08 | 2024-07-12 |
| An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. sepofarsen - Leber Congenital Amaurosis 10, Blindness | Phase 2 / Phase 3 | Unknown | ProQR Therapeutics | 15 | 2021-03-23 | 2022-03-25 |
| Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO treatment - Arteritis, Giant Cell, Blindness and Low Vision | Phase 3 | Completed | Centre Hospitalier Universitaire de Nice | 8 | 2020-02-04 | 2026-06-18 |
| A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) sepofarsen, Sham - Leber Congenital Amaurosis 10, Blindness | Phase 2 / Phase 3 | Active not recruiting | ProQR Therapeutics | 36 | 2019-04-04 | 2022-03-17 |
| Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration Aflibercept - Macular Degeneration, Wet Macular Degeneration | Phase 3 | Completed | Centre Hospitalier Intercommunal Creteil | 84 | 2013-12-01 | 2026-10-27 |
| Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception tasimelteon - Non-24-Hour Sleep-Wake Disorder | Phase 3 | Completed | Vanda Pharmaceuticals | 200 | 2011-10-01 | 2015-04-21 |
| Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder tasimelteon, Placebo - Non-24-Hour Sleep-Wake Disorder | Phase 3 | Completed | Vanda Pharmaceuticals | 20 | 2011-09-01 | 2014-10-10 |
| Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception tasimelteon - Non 24 Hour Sleep Wake Disorder | Phase 3 | Unknown | Vanda Pharmaceuticals | 140 | 2010-10-28 | 2024-04-03 |
| Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder tasimelteon, Placebo - Non-24-Hour Sleep-Wake Disorder | Phase 3 | Completed | Vanda Pharmaceuticals | 136 | 2010-08-01 | 2014-10-16 |
| Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) Ranibizumab, Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) - Macular Degeneration | Phase 3 | Completed | Bayer | 1240 | 2008-04-01 | 2014-12-12 |
| Preventing Depression in Patients With Macular Degeneration Problem Solving Treatment, Control - Depression, Macular Degeneration | Phase 3 | Completed | Thomas Jefferson University | 206 | 2001-02-01 | 2014-01-08 |
| Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity Supplemental Oxygen Management, Conventional Oxygen Management - Infant, Newborn, Infant, Low Birth Weight | Phase 2 / Phase 3 | Completed | NICHD Neonatal Research Network | 649 | 1994-02-01 | 2015-06-08 |
Showing 20 of 22. Sign in to see all of them.
Eye Diseases (13) · Vision Disorders (8) · Retinal Diseases (7) · Eye Abnormalities (5) · Retinitis Pigmentosa (5) · Usher Syndromes (5) · Chronobiology Disorders (4) · Dyssomnias (4) · Eye Diseases, Hereditary (4) · Nervous System Diseases (4) · Sleep Disorders, Circadian Rhythm (4) · Sleep Wake Disorders (4) · Leber Congenital Amaurosis (3) · Leber Congenital Amaurosis 10 (3)
Pathological Conditions, Signs and Symptoms (22) · Signs and Symptoms (22) · Neurologic Manifestations (19) · Sensation Disorders (19) · Nervous System Diseases (18) · Vision Disorders (14) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9) · Eye Diseases (9) · Congenital Abnormalities (8) · Genetic Diseases, Inborn (7) · Retinal Degeneration (7) · Retinal Diseases (7) · Abnormalities, Multiple (5) · Deaf-Blind Disorders (5)
aflibercept (4) · tasimelteon (4) · Intravitreal Injections (2) · Acetylcysteine (1) · Aspirin (1) · Light Coagulation (1) · N-Acetylcysteinamide (1) · Ranibizumab (1) · Therapeutics (1) · salicylhydroxamic acid (1)
Vanda Pharmaceuticals (4) · Laboratoires Thea (3) · Adverum Biotechnologies, Inc. (2) · Nacuity Pharmaceuticals, Inc. (2) · National Eye Institute (NEI) (2) · ProQR Therapeutics (2) · Bayer (1) · Centre Hospitalier Intercommunal Creteil (1) · Centre Hospitalier Universitaire de Nice (1) · Hancock Jaffe Laboratiores, Inc (1) · Johns Hopkins University (1) · NICHD Neonatal Research Network (1) · Thomas Jefferson University (1)
United States (13) · Germany (7) · United Kingdom (7) · France (6) · Netherlands (6) · Belgium (4) · Brazil (4) · Canada (4) · Italy (3) · Australia (2) · Austria (2) · Spain (2) · Switzerland (2) · Argentina (1) · Colombia (1)
Adam Turpcu, PhD (2) · Alan R. Spitzer, MD (1) · Barbara J. Stoll, MD (1) · Beverly S. Brozanski, MD (1) · Charles C. Barr, MD (1) · Cynthia Cole, MD (1) · Dale L. Phelps, MD (1) · David Easa, MD (1) · David K. Stevenson, MD (1) · Edward F. Donovan, MD (1) · Eric Souied, MD (1)
PMID 26466871, PMID 10654946, PMID 17679633, PMID 23084240, PMID 23528439, PMID 24084500, PMID 25107900, PMID 25439429, PMID 30681643, PMID 31826853, PMID 36932356, PMID 41282901, PMID 42635483
1UG1EY033293 (1), 2018 (1), M01RR000054 (1), M01RR000070 (1), R01MH061331 (1), U10HD021385 (1), U10HD021415 (1), U10HD027851 (1), U10HD027853 (1), U10HD027856 (1), U10HD027871 (1), U10HD027880 (1), U10HD027904 (1), U10HD040689 (1)